Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.
External link for Eikonizo Therapeutics
700 Main Street North
Cambridge, MA 02139 , US
Eikonizo Therapeutics reposted this
I was very grateful to attend #alsmndsymp and have the opportunity to present the latest from Eikonizo Therapeutics on our lead program EKZ-102. I learned a lot and met so many wonderful people in the community. Looking forward to the next one!
Today we also announced key additions to strengthen our leadership, including Tom Hughes, who joins our Board, as well as Richard Fisher as CSO, Jim Luterman as EVP, Development and Jon Graves as VP, Finance and Controller. Learn more here: https://lnkd.in/gMKGRehR
We’re thrilled to announce an investment by Novo Nordisk which will support development of our lead candidate EKZ-102 for ALS and other neurodegenerative diseases and enable the advancement of our novel HDAC6 inhibitors as potential disease-modifying therapeutics for cardiorenal disease. EKZ-102 is a highly selective, uniquely CNS-penetrant HDAC6 inhibitor with strong potential to be a first-in-class, disease-modifying therapy for ALS and other indications. Read the PR here: https://lnkd.in/eYSJcTBp
Great to see so many friends at #alsmndsymp this weekend! Thanks Tonya M. Gilbert, PhD for sharing the latest on our lead program, EKZ-102!
Eikonizo Therapeutics reposted this
NOV 13-15th: Join us for our 7th Annual ALS Research Symposium! Come gather with us from afar (held via Zoom so that anyone can attend easily from anywhere in the world), for our highly anticipated 3-day annual conference & listen in on presentations & talks from many of the world’s most prominent leaders in ALS research. On DAY 1 (11/13), 12 renowned ALS keynote speakers will give talks on important ALS topics including: The current clinical trials landscape, Innovation in trial design, New approaches to understanding sporadic ALS, miRNA’s, Somatic mosaicism, IPSCs modeling, the ALS exposome, subclassification, using neurofilament in clinical trials, ALS risk factors, outcome measures, ALL ALS, & more, from these esteemed researchers: Sabrina Paganoni, MD, PhD, Jeremy Shefner, MD, PhD, FAAN, Melanie Quintana, PhD, James Berry, MD, MPH, Jaime Raymond, MPH, Stephanie Melillo Fradette, PharmD, Ammar Al-Chalabi, PhD, Eran Hornstein, PhD, Justin Ichida, PhD, Eva Feldman, MD, PhD, Zinan Zhou, PhD, Dame Pamela Shaw, MD, FAAN, along w/moderators, Dr.’s Sabrina Paganoni and Robert Brown. On DAY 2 (11/14), presentations will be given from 19 members of the ALS pharma industry about current trials for which they are currently working or have recently completed towards effective treatments for ALS. We’ll hear from Acelot, Aclipse Therapeutics, Amylyx Pharmaceuticals, Arbor Technologies, Axoltis Pharma, Eikonizo Therapeutics, Kadimastem Ltd., Leal Therapeutics, Mitochon Pharmaceuticals, Inc., Modality.AI, Neurizon, NeuroSense Therapeutics, OrphAI Therapeutics, PLL Therapeutics, Prilenia, Spinogenix, Inc., Transposon Therapeutics, Inc., uniQure, Zydus Group Lifesciences. Day 2 will be moderated by James Berry, MD, MPH, and Fernando Vieira, MD. On DAY 3 (11/15), Indu Navar & EverythingALS, along with Leigh Hochberg, MD, PhD from The Ctr for Neurotech & Neuro-Recovery at MGH will converse with industry leaders from renowned companies including Compass AI, Critical Path Institute (C-Path), MGH, MIT, Passio AI, Regeneron, Microsoft, Modality, Temple University, and more. The focus will be on sharing the effects & outcomes of the transformative power of collaboration between tech companies, pharmaceutical giants, and academic institutions. Explore how AI & neurotechnology are driving innovation & accelerating the development of new treatments and technologies for ALS. With immense gratitude to our Symposium Sponsors: Mitsubishi Tanabe Pharma America, Amylyx Pharmaceuticals, Biogen, Sanofi, Spinogenix, Inc., and QurAlis. This conference would not be possible without your generosity! All are welcome & reg is free but required at https://lnkd.in/gi2yUywH . #ALS #ALSResearchSymposium #ALSconference #ALSGlobalSymposium #ALSVirtualSymposium #AllAreWelcome #ALSONEResearchSymposium #RegisterForFree
We are looking forward to sharing updates on our research this afternoon at the ALS ONE Research Symposium. Thanks for inviting us ALS ONE team! More info on the 7th Annual ALS Research Symposium can be found here: https://lnkd.in/gi2yUywH #ALS #endals
Eikonizo Therapeutics researcher Rebecca James (she/her), Ph.D. is on site at #SfN24 in Chicago, ready to discuss our data in #Parkinsons disease. Stop by poster #D19 from 1-4pm CT today and say hi!
Eikonizo Therapeutics is taking it on the road this month to showcase the breadth of our data across #neurodegenerative diseases, including #ALS, #FTD and #Parkinsons. Stop by our posters at #SfN24 in Chicago on 10/9 and at #NEALSMtg in FL on 10/23 to learn more! Society for Neuroscience Northeast ALS Consortium (NEALS)
September is #WorldAlzheimersMonth and Eikonizo Therapeutics is proud to join forces with the Alzheimer's and dementia community to raise awareness for Alzheimer’s disease and all types of dementia. Check out this link for more information on World Alzheimer's Month: https://lnkd.in/eGsXmt4K Alzheimer's Drug Discovery Foundation #dementiaawareness #AlzheimersAwareness #2024WorldAlzheimersMonth #AlzheimersDiseaseInternational #WorldAlzMonth
QurAlis thanks Eikonizo Therapeutics for the #icebukcetchallenge nomination - challenge accepted! We are honored to participate to raise #ALSawareness as part of the 10th Anniversary of the ALS Ice Bucket Challenge. QurAlis' CEO and co-founder Kasper Roet and CTO Hagen Cramer got “soaked” on behalf of QurAlis. In the spirt of community building and to keep the positivity flowing, QurAlis challenges Leal Therapeutics, ProJenX, and NeuroSense Therapeutics to complete the Ice Bucket Challenge. Let’s continue to spread the word for ALS research and a cure! #icebucket10 #fratetrain #precisionmedicine #neurodegenerativediseases